GROWTH-HORMONE TREATMENT IN GROWTH-RETARDED CHILDREN WITH END-STAGE RENAL-FAILURE - EFFECT ON FREE DISSOCIABLE IGF-I LEVELS

Citation
A. Bereket et al., GROWTH-HORMONE TREATMENT IN GROWTH-RETARDED CHILDREN WITH END-STAGE RENAL-FAILURE - EFFECT ON FREE DISSOCIABLE IGF-I LEVELS, Journal of pediatric endocrinology & metabolism, 10(2), 1997, pp. 197-202
Citations number
25
Categorie Soggetti
Pediatrics,"Endocrynology & Metabolism
ISSN journal
0334018X
Volume
10
Issue
2
Year of publication
1997
Pages
197 - 202
Database
ISI
SICI code
0334-018X(1997)10:2<197:GTIGCW>2.0.ZU;2-F
Abstract
Growth retardation in children with end-stage renal disease (ESRD) is associated with normal to slightly low concentrations of insulin-like growth factor (IGF)-I and increased concentrations of IGF-binding prot eins (IGFBPs) in serum, Consequently, IGF-I bioactivity is reduced in serum from uremic patients presumably due to a decrease in the concent ration of free IGF-I, Improvement of linear growth with growth hormone (GH) treatment of uremic children is thought to be due to increased I GF-I/IGFBP ratio, thus resulting in increased free IGF-I levels during treatment, The purpose of the present study was to determine whether free/dissociable TGF-I levels are in fact low in uremic children and w hether increased growth velocity during GH treatment is associated wit h an increase in the free IGF-I concentration, Serum total and free/di ssociable IGF-I concentrations were measured in 5 children with ESRD b efore and during treatment with GH, and in control children matched fo r age, pubertal status, and body mass index, Height velocity increased from 3.7 +/- 1.0 cm/yr to 6.5 +/- 1.2 cm/yr with an increment in heig ht SDS at the end of the first year of GH treatment, Free/dissociable IGF-I concentrations tended to be lower in uremic children compared to control children (3.0 +/- 0.3 vs 7.3 +/- 2.1 mu g/l, respectively). D uring GH treatment, free/dissociable IGF-I levels increased significan tly to 8.5 +/- 1.0 mu g/l at 3 months and 6.9 +/- 1.4 mu g/l at 6-24 m onths, p<0.05 compared to pretreatment. Total IGF-I levels were 243 +/ - 18 mu g/l in children with ESRD before treatment and these values al so increased during GH treatment (740 +/- 114 mu g/l at 3 months and 4 42 +/- 44 mu g/l at 6-24 months, p<0.05, compared to pretreatment), To tal IGF-I concentration in the control group was 439 +/- 114 mu g/l, T hese results support the hypothesis that growth retardation in childre n with chronic renal failure is associated with a reduction in the con centration of free, biologically available IGF-I, and that increased g rowth velocity during GH treatment of these children is associated wit h restoration of free IGF-I concentrations.